On Tuesday, Concord Biotech Ltd (CONCORDB:IN) shares had its price target increased by a brokerage firm from INR1,550.00 to INR1,650.00, while the stock's rating remained at an Add (2). The adjustment comes despite Concord Biotech's first-quarter financial results for fiscal year 2025 falling short of expectations.
The company's sales, EBITDA, and PAT were below estimates by 6%, 5%, and 12%, respectively, primarily due to weaker API sales and a delay in the start of its injectables facility.
Despite the quarterly performance, Concord Biotech remains optimistic about its growth prospects. The company has reiterated its guidance, aiming for a 25% sales compound annual growth rate (CAGR) over the next five years. This confidence is based on stable pricing and market shares, which Concord expects to maintain moving forward.
The brokerage firm's analysis indicates that Concord Biotech is positioned to capitalize on strong underlying demand trends. The company plans to grow its market share in existing molecules, a strategy supported by recent capacity expansions that have freed the company from previous constraints. Additionally, Concord is looking forward to the introduction of new products.
The firm forecasts that these factors, combined with the company's growth strategy, will enable Concord to achieve a robust 27% earnings per share (EPS) CAGR from fiscal year 2024 to 2027. This projection takes into account the company's potential for expansion and its plans to launch new offerings in the market.
The price target increase reflects the firm's belief in Concord Biotech's ability to navigate through current challenges and capitalize on market opportunities. Concord's dedication to its growth outlook and the expected positive impact of its strategic initiatives have been the key drivers behind the firm's decision to maintain the Add (2) rating and raise the price target.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.